| genetic
disease, genetic engineering, custom chip design, genotyping
services, human high-throughput genotyping, microarray design,
genome, Apex, development, arrayed primer extension, SNP,
genomics, genetic testing services, SNP tests, DNA chip, arrayed primer
extension, microarray scanner, p53, drug development,
diagnostics, personalized treatment,
human medicine, SNP, biotechnology, technology transfer, gene, DNA test |
NEWS
of 2001
08.2001 - Asper sells Genorama®
QuattroImager to Columbia
University.
Asper Biotech signed an agreement
to sell Genorama genotyping
and SNP scoring system to the Columbia University (New York, USA). The sale of the system
will continue a 1-year long collaboration between the partners, where
Asper provides Columbia University with mutation screening services.
Asper sees the new contract as an acknowledgement to its genotyping
services and products.
08.2001 - Asper announces release of TP53 tumor suppressor gene sequencing
and mutation detection chip.
Identification of mutations in the TP53 tumor suppressor gene is
crucial for molecular epidemiology as well as for molecular pathology of
human cancer. The TP53 gene chip spans exons 2 to 9 plus two introns from
both strands. Each base is probed with two primers, one for the sense and
another for the antisense strand (total of 2436 oligonucleotides for 1218
identified basepairs). The TP53 chip is open for improvements and
expanding. Additional regions of the TP53 gene can be easily added to the
assay depending on the customer requirements. Preliminary evaluations have
shown that the APEX-based TP53 mutation assay provides an accurate and
cost-efficient tool for DNA sequence analysis of this frequently mutated
gene as well as other genes of interest.
07.2001 - Asper has one-year experience in genetic services and
product development according to ISO 9001 quality standards.
Asper’s product development and genotyping service was certified to
be in accordance with ISO 9001 quality standards in July 2000. The one
year follow-up evaluation July 2001 revealed that the standards have
become a routine in the company’s everyday management. The quality
certificate has become a valuable argument for many of the customers to
use Asper’s genotyping services, based on novel technological platform.
04.2001 - Asper has reached 25
000 genotypes a day throughput.
Asper Biotech has developed a DNA
microarray to screen about 1400 SNP-s located in the human chromosome 22.
During the project Asper has reached the capacity up to 25 000 genotypes
per day. The genetic material from up to 20 individuals is prepared and
amplified, SNP-s detected with APEX and the data analyzed. Up to 300
persons will be investigated in total.
03.2000 - International Agency for Research on Cancer (IARC) in
Lyon, France purchased Asper’s Genorama® QuattroImager.
IARC, a part of World Health Organization purchased Asper’s GenoramaTM
QuattroImager to implement Arrayed Primer Extension (APEX) technology for
research on hereditary factors on tumorigenesis. APEX was chosen because
the commonly used genotyping methods do not offer the needed capacity and
cost-efficiency for current epidemiological studies involving large groups
of individuals and identification of hundreds to thousands of
polymorphisms per individual.
02.2001 - Goodgene and Asper will co-operate in several Asian
countries.
Asper Biotech has granted
Goodgene (Seoul, Korea) non-exclusive rights to distribute Asper’s
Genorama® genotyping system in several Asian countries. The distribution
partnership with GoodGene provides Asper the chance to strengthen its
position in Asian life science market.
Asper has provided chip development and
genotyping services to GoodGene. As a next step in the co-operation
GoodgGene purchased Genorama® QuattroImager from Asper. The system will
also be a demo-lab for Asian market.
|
|
Genorama®
SAL
Genorama®
SA
|
